ImmunoPrecise Antibodies (STU:TQB) Debt-to-EBITDA : -2.69 (As of Oct. 2024)

ImmunoPrecise Antibodies Debt-to-EBITDA Chart

ImmunoPrecise Antibodies Annual Data
	Trend	Dec14	Dec15	Apr17	Apr18	Apr19	Apr20	Apr21	Apr22	Apr23	Apr24
Debt-to-EBITDA		Get a 7-Day Free Trial					-10.04	-2.44	-0.23	-0.35	-0.60

ImmunoPrecise Antibodies Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
Debt-to-EBITDA	Get a 7-Day Free Trial															-1.94	-1.68	-0.20	-1.19	-2.69

Competitive Comparison of ImmunoPrecise Antibodies's Debt-to-EBITDA

For the Biotechnology subindustry, ImmunoPrecise Antibodies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmunoPrecise Antibodies's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunoPrecise Antibodies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ImmunoPrecise Antibodies's Debt-to-EBITDA falls into.

ImmunoPrecise Antibodies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

ImmunoPrecise Antibodies's Debt-to-EBITDA for the fiscal year that ended in Apr. 2024 is calculated as

ImmunoPrecise Antibodies's annualized Debt-to-EBITDA for the quarter that ended in Oct. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Oct. 2024) EBITDA data.

ImmunoPrecise Antibodies  (STU:TQB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

ImmunoPrecise Antibodies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ImmunoPrecise Antibodies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunoPrecise Antibodies Business Description